Ifosfamide-Induced Encephalopathy in Children and Young Adults: The MD Anderson Cancer Center Experience. (2025)

Peer-Reviewed Study · Alqahtani S, Bitar SD, Mireles ME, Corrales-Medina FF, Herzog CE, Slopis J, Daw NC · June 29, 2025

Alqahtani S et al., 2025-06-29: MD Anderson review of 24 children and young adults with ifosfamide encephalopathy: 83% received methylene blue with symptom resolution in 19, but 3 of 5 given prophylaxis on re-challenge had recurrence.

Twenty patients (83%) received methylene blue, with symptom resolution in nineteen patients (83%).

Alqahtani S et al., 2025-06-29: MD Anderson review of 24 children and young adults with ifosfamide encephalopathy: 83% received methylene blue with symptom resolution in 19, but 3 of 5 given prophylaxis on re-challenge had recurrence. C6. Study type: retrospective institutional case review over 10 years; University of Texas MD Anderson Cancer Center, USA. N=24, median age 17.6 years (4-30), 71% bone/soft tissue sarcoma; ifosfamide 1.5-3.3 g/m2/day; IIE at median cumulative dose 18 g/m2; 12 after short infusions, 12 after continuous infusions. 20 received methylene blue, resolution in 19; 10 re-challenged, 5 with prophylaxis, 3 recurred. Dose of methylene blue not stated in the abstract. Authors declare no conflicts of interest. Funders not stated in the record. Comparator: none. Study type: uncontrolled series.